138
Views
4
CrossRef citations to date
0
Altmetric
Review

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

, &
Pages 503-510 | Published online: 19 Jun 2013

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and a paucity of therapeutic options. Nintedanib (previously known as BIBF 1120) is a tyrosine kinase receptor antagonist which inhibits a number of key receptors, including those for platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF). These growth factors are profibrotic and each has been investigated as a potential standalone therapeutic target in IPF. Simultaneous inhibition of these receptors, with an analog of nintedanib, has proved to be effective in experimental animal models of pulmonary fibrosis. This observation, together with extensive safety and pharmacokinetic data from studies of nintedanib in malignancy, paved the way for the clinical development of this drug in IPF. The Phase IIb TOMORROW trial demonstrated that treatment with nintedanib may potentially slow decline in lung function, decrease the frequency of acute exacerbations, and improve quality of life in patients with IPF. While these observations are drawn from a single clinical trial, taken together with the preclinical data they suggest that nintedanib may yet become an important therapeutic option for individuals with IPF. The results of ongoing parallel, international, multicenter Phase III clinical trials are therefore eagerly awaited.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease which has no clear etiology.Citation1 It is the most common of all the idiopathic interstitial pneumonias, affecting seven to 16 people per 100,000 each year, and its incidence is rising.Citation2Citation5 Lack of a proven effective therapy means prognosis is poor, with a median survival of 3 years post diagnosis.Citation6

The mechanisms underlying the development and progression of IPF remain poorly understood, but current theories propose that the condition develops as a result of an aberrant wound healing response to repeated alveolar injury in genetically susceptible individuals.Citation1 The consequence of this response is uncontrolled myofibroblast proliferation and differentiation, and abnormal extracellular matrix deposition, with excess collagen accumulation in the interstitium. Normal lung architecture is destroyed and replaced by scar tissue, which compromises lung function, resulting in progressive respiratory failure. The process of fibrosis is driven by myriad growth factors and their downstream intra-cellular signaling pathways. It is therefore unsurprising that multiple cell signaling pathways have been identified as potential therapeutic targets in IPF.Citation7,Citation8 Despite these preclinical observations, pirfenidone, which was approved in Japan in 2008 and Europe in 2011, is the only licensed treatment currently available for individuals with IPF.Citation9

Nintedanib, formally known by the development code BIBF 1120, is an orally available 6-methoxycarbonyl-substituted indolinone (indolinones are either of two isomeric ketones derived from indoline, which itself is a bicyclic secondary amine consisting of fused benzene and pyrrolidine rings),Citation10 which acts as a multiple-receptor tyrosine kinase inhibitor, and has recently shown promising results in a Phase II trial in IPF.Citation11 Originally developed as a cancer treatment, nintedanib acts by simultaneously inhibiting three receptor families implicated in angiogenesis: platelet derived growth factor (PDGF); vascular endothelial growth factor (VEGF); and fibroblast growth factor (FGF).Citation10 Single angiogenic inhibitors, such as those antagonizing VEGF receptors, have historically had limited success in clinical practice, due to redundancy in angiogenic pathways provided by a variety of proangiogenic growth factors including FGF and PDGF. Multiple-target receptor tyrosine kinase inhibitors, including nintedanib, have been developed to address this problem.Citation12 Nintedanib has entered clinical trials for numerous malignancies, where it targets the neovascularization critical for tumor growth and metastasis.Citation12Citation18 Phase III trials are ongoing in non-small-cell lung (LUME-Lung 1 and 2; NCT00805194, and NCT 00806819 respectively) and ovarian cancer (LUME-Ovar1; NCT01015118).

Importantly, PDGF, VEGF, and FGF are also critical profibrotic mediators which have been shown to play a role in driving the development of fibrosis.Citation19 Encouraging results using nintedanib or its analog BIBF 1000 in vitro and in animal models of experimentally induced fibrosis, have paved the way for clinical development of the compound in IPF.Citation19 The recent publication of a large Phase IIb studyCitation11 in IPF and the anticipated completion of two concurrent Phase III trials has raised the hope that nintedanib may prove to be an effective therapy for IPF. This review therefore aims to provide a synopsis of the current state of knowledge regarding the pharmacodynamics, pharmacokinetics (PK), therapeutic efficacy, and toxicity of nintedanib, based on the published literature.

Preclinical validation

Nintedanib is a potent, oral, small, molecule, intracellular inhibitor of the receptor tyrosine kinases PDGF receptor (R)-α and -β (IC50 59 and 65 nmol/L), VEGFR-1, -2, and, -3 (IC50 s 13–34 nmol/L) and FGFR-1, -2, and -3 (IC50s 37–108 nmol/L).Citation10 Profiling of the human kinome demonstrates that nintedanib also inhibits a narrow range of other targets at pharmacologically relevant doses eg, Src family and Flt-3 kinases. Nintedanib competitively binds the ATP pocket binding site of its target receptor tyrosine kinase, resulting in interference of receptor dimerization and autophosphorylation of the tyrosine kinase domains, and inhibition of downstream signaling.Citation12 The exact receptor-binding kinetics are not completely understood, however, it has been shown that nintedanib causes sustained (>32 hours) inhibition of VEGFR-2 phosphorylation in pulse-chase experiments of VEGFR-2-transfected NIH3T3 cells.Citation10

In preclinical oncology experiments with human tumor xenografts, nintedanib is effective in reducing tumor growth through inhibition of angiogenesis.Citation20 At present only limited data have been published on the effect of BIBF on fibrogenesis either in vitro or in vivo in animal models. The main published work assessing tyrosine kinase receptor inhibition in fibrosis utilized an analog of nintedanib, BIBF 1000.Citation19 Chaudhary et alCitation19 demonstrated that 50 mg per kg BIBF 1000, when dosed both prophylactically and therapeutically, inhibits the development of fibrosis in the rat bleomycin model (measured at day 22 by Masson’s trichrome and procollagen 1 gene expression). The authors were also able to show that in in vitro experiments BIBF 1000, but not imatinib mesylate, blocks TGF-β-induced fibroblast to myofibroblast transformation, via SMAD independent pathways. Although TGF-β acts as a potent profibrotic mediator, at physiological levels it is important in tissue homeostasis and acts as a modulator of inflammation and cell proliferation. The ability of BIBF 1000 to inhibit myofibroblast differentiation without affecting the canonical SMAD signaling pathway is potentially advantageous, particularly because studies in knockout mouse models suggest that global inhibition of TGF-β as a strategy to treat fibrosis could have adverse side effects, such as inducing widespread inflammation and increasing the risk of malignancy.Citation21

Although there is a paucity of pre-clinical data supporting the antifibrotic potential of nintedanib, an antifibrotic effect can be predicted from the compound’s capacity to inhibit PDGF, FGF, and VEGF. PDGF comprises a family of dimers of two polypeptide chains, A and B. These dimers interact with PDGF-α or -β tyrosine kinase receptors, resulting in activation of downstream Pi3K and MAPK pathways. PDGF-A and PDGF-B are potent fibroblast mitogens and chemotractants. In addition, in vitro, PDGF is important in mediating TGF-β, IL-1, TNFα, FGF, and thrombin fibrotic responses.Citation22Citation26 In rat lung, administration of an adenoviral vector containing PDGF-B results in a mild fibroproliferative response.Citation27 Furthermore, PDGFR selective tyrosine kinase inhibitors have been shown to reduce pulmonary fibrosis in a rat model of vanadium pentoxide induced lung injuryCitation28 and a murine model of radiation induced fibrosis.Citation29 PDGF is synthesized by alveolar macrophages.Citation23 Macrophages extracted from bronchoalveolar lavage fluid from patients with IPF produce four times the amount of PDGF compared to macrophages from normal lungs.Citation30 In IPF, hyperplastic type II pneumonocytes strongly express messenger ribonucleic acid (mRNA) for PDGF-B and for PDGF receptors.Citation31 Fibroblasts derived from IPF also produce PDGF.Citation31 Imantinib mesylate, a PDGFR and cAbl inhibitor, reduces murine bleomycin-mediated lung fibrosis when administered prophylactically.Citation32 However, in a Phase IIb clinical trial, while imantinib-treated subjects showed significant improvement in oxygenation at 48 weeks, there were no significant differences in the primary endpoints of survival or improvement in lung function compared to placebo.Citation33 While these data might argue against the efficacy of PDGF targeted therapy, rodent studies have suggested that one of the mechanisms of action of the novel antifibrotic agent pirfenidone is inhibition of PDGF synthesis.Citation34

The FGFs are a family of pluripotent growth factors which act on many different cells types via high affinity FGFRs including FGFR-1 and -2. Basic (b) FGF (also known as FGF-2) potently induces the proliferation of many cell types involved in wound healing, including fibroblasts, endothelial cells, and smooth muscle cells. High levels of bFGF have been found in bronchoalveolar lavage and serum of patients with IPF.Citation35,Citation36 Production of bFGF by type II pneumonocytes is stimulated by TGF-β.Citation37,Citation38 In vitro, FGFR-1 inhibitors reduce murine fibroblast proliferation and in a murine bleomycin model of fibrosis, administration of a soluble mutant FGF receptor with high binding affinity for bFGF attenuated fibrosis.Citation39

VEGF is a critical mediator of angiogenesis which drives endothelial cell proliferation and vessel formation predominantly through VEGFR-2.Citation40 Interestingly, in a rat model of adenoviral TGF-β overexpression-induced pulmonary fibrosis, VEGF increases microvessel density and attenuates the development of pulmonary hypertension but at the cost of exaggerated fibrosis.Citation41 Angiogenesis is important in the normal wound healing response. Aberrant neovascularization is a recognized histological feature in IPF tissue, with marked regional heterogeneity in vascular density.Citation42 In general, vascularity is increased in areas bounding fibrosis while fibroblastic foci are hypovascular. Although the exact role of angiogenesis in the fibrotic process is still debated, increased angiogenic activity secondary to an imbalance in angiogenic and angiostatic factors is seen in human fibrotic lung tissue.Citation43 PDGF and FGF act synergistically to induce endothelial cell proliferation, and contribute to pericyte recruitment and stability of blood vessel walls.Citation44 Early administration of a VEGFR-2 inhibitor or a soluble VEGF-1 decoy receptor in the murine bleomycin model attenuates fibrosis, microvessel formation, and bronchoalveolar lavage inflammatory cell counts.Citation45 In vitro, nintedanib inhibits VEGF-, PDGF-, and FGF-mediated proliferation of the three cell types contributing to angiogenesis: endothelial cells; vascular smooth muscle cells; and pericytes (EC50 10–79 nmol/L). In vivo, nintedanib reduces tumor microvessel density.Citation12

Pharmacokinetics

Extensive data on the PK of nintedanib have been derived from trials in subjects with malignancy. Several Phase I studies have examined the safety and pharmacokinetic parameters of nintedanib as a monotherapyCitation46 or in combination with other chemotherapeutic agents.Citation14Citation16 In a 4-week Phase I accelerated dose titration study of nintedanib monotherapy in 61 individuals with advanced solid malignancies, subjects were treated with escalating doses of oral nintedanib, to a maximum dose of 450 mg once daily or 300 mg twice daily. PK profiles were measured at a steady state. Absorption of oral nintedanib was relatively fast, with maximum concentration (Cmax) reached at 1–3 hours following twice-daily dosing. The Cmax and exposure, as measured by the area under the curve, increased with increasing doses of nintedanib. The volume of distribution ranged from 10.1–25.4 L depending on the dose, suggesting a high tissue distribution. It should be noted however, that the bioavailability of nintedanib was not calculated. In this study, a terminal half-life (t1/2) of 12.9–19 hours was observed. There was, however, significant variability in the PK parameters between subjects which the authors attributed to the mixed nature of the study cohort. The maximum tolerated dose was 250 mg. Twice daily administration of this dose was better tolerated, with greater drug exposure, than higher doses given once daily.

Okamoto et al conducted a similar Phase I trial of nintedanib in Japanese patients with advanced solid malignancy.Citation47 The maximum tolerated dose in this cohort was 200 mg twice daily. Multiple dosing PK measurements were in keeping with data from other studiesCitation17,Citation46 with fast absorption, Cmax at 2–3 hours and a terminal t1/2 of 19–23 h. In a study of eight healthy white male volunteers (mean age 32.3 years), the PK and metabolism of a single dose of [14C]-radiolabeled nintedanib was analyzed. Following fasted administration of an oral solution of 100 mg, nintedanib was detected in plasma at 15 minutes, with Cmax achieved at 1.3 hours.Citation48 Mean t1/2 was 13.7 hours and the area under the curve was 61.3 ng·h/mL.

In vitro, nintedanib is rapidly metabolized by hepatocytes via ester cleavage to form the metabolite BIBF 1202. Extensive metabolite pattern analysis undertaken on the plasma, urine, and feces of healthy human volunteers after administration of [14C]-radiolabeled nintedanib revealed BIBF 1202 and its glucuronic acid conjugate, 1-0 acylglucorinde as the most prevalent metabolites.Citation48 In healthy volunteers, BIBF 1202 was detected along with the parent compound 15 minutes after nintedanib administration with Cmax for BIBF 1202 being reached at 2.5 hours. The authors speculate that the rapid appearance of the metabolite results from first pass metabolism in the intestinal wall. The major route of metabolite elimination is via the liver and through excretion in feces. There is minimal excretion in the urine.

The hepatic metabolism of nintedanib is mainly CYP450 independent.Citation49 Consequently, there is a lack of inhibition of CYP450 enzymes (inhibitory concentration [IC]50 >50 μM) by nintedanib, BIBF 1202, and 1-0 acylglucuronide and there have been no reported drug–drug interactions from clinical trials in malignancy. A trial examining the effect of ketoconazole on the pharmacokinetics of nintedanib in healthy volunteers is currently underway (ClinicalTrials.gov identifier: NCT01679613). There are no published PK studies in patients with IPF.

Clinical trials of nintedanib in IPF

With the safety of nintedanib having been established in oncology studies, and animal data suggesting an antifibrotic role for the compound, it was logical that the drug be trialled in patients with IPF. The TOMORROW (To imprOve pulMOnaRy fibROsis With BIBF1120) study, a 12-month double blinded, randomized, dose-ranging placebo-controlled Phase II trial investigating the efficacy and safety of nintedanib in IPF, reported in 2011.Citation11 Richeldi et al randomized 432 subjects to receive one of four nintedanib dosing regimens (50 mg once daily, 50 mg twice daily, 100 mg twice daily, or 150 mg twice daily) or placebo. An increasing dose strategy was initially employed, with safety data reviewed by an independent committee before each dose escalation. The primary endpoint for the study was the annual rate of forced vital capacity (FVC) decline. Secondary endpoints measured included absolute change in FVC, total lung capacity, total lung diffusion capacity for carbon monoxide (DLCO), 6-minute walk distance, acute exacerbation rate, quality of life (measured with the St George’s Respiratory Questionnaire [SGRQ]), and survival.

At the time of enrollment, patients had, on average, mild to moderate IPF with a mean FVC of 81.3% predicted, a mean DLCO of 3.8 mmol/minute/kPa, and median resting oxygen saturations of 96%. In terms of diagnostic certainty, there were 141 (32.9%) definite, 265 (61.9%) probable, and 21 (4.9%) possible cases of IPF (one individual was found not to have IPF). Of the 428 enrolled subjects 128 had been diagnosed with IPF following surgical lung biopsy. Study subjects were permitted concomitant therapy with up to 15 mg daily of prednisolone. Use of either N-acetyl cysteine or pirfenidone was an exclusion criteria and neither was permitted for the duration of the study.

A number of challenges face IPF clinical trial investigators. Firstly the choice of primary endpoint remains contentious.Citation50Citation52 There is, however, an emerging consensus, backed by a growing body of data that change in FVC provides a reasonable surrogate for longer term prognosis and survival.Citation51,Citation53 Furthermore, a recent analysis by du Bois et al,Citation51 using data from several published IPF clinical trials, has demonstrated that the minimal clinically important difference in FVC over 12 months lies between 2% and 6%. The second challenge is that of handling missing data. While this is a problem in all clinical trials, it is one that tends to be magnified in IPF due to the length of the studies and the progressive nature of the disease (resulting in study subjects who die or become too unwell to undertake spirometry). Simplistic handling of missing data has hampered the interpretation of previous IPF clinical trials.Citation54,Citation55 In the TOMORROW study, the investigators calculated the change in FVC for every individual by modeling the linear decrease in FVC for each subject from the time of first dose until the last study observation undertaken for that subject. This modeling took into account all FVC readings performed by each subject during the study and ensured robust handling of missing data values.Citation11

Because of the multiple dosing groups included in the study, analysis of the primary endpoint was with a closed hierarchical testing procedure, with correction for multiplicity. The multiplicity correction, added to avoid type I error, raised the threshold required for the study to achieve statistical significance. Using this approach the pre-defined primary endpoint did not differ significantly (P = 0.06) between the group of subjects receiving the highest dose of nintedanib (150 mg twice daily) and the placebo. However, the annual rate of decline in the 150 mg twice daily group was 0.06 L compared to 0.19 L in the placebo group. Hierarchical comparison of these groups (without correction for multiplicity) pointed towards a significant difference between groups (P = 0.01). Subsequent, post hoc, sensitivity analyses of the primary endpoint using a conservative, closed testing procedure adjusting for multiplicity, show significant differences between the placebo and the highest dose group with: (1) inclusion of baseline values and unscheduled visits (P = 0.0058); (2) analysis by final dose (P = 0.0047); (3) use of data from week 6 only (P = 0.0202); and (4) inclusion of time as a fixed effect in the model (P = 0.0007).Citation56

Despite the study’s failure to achieve the primary endpoint, there were a number of clinically important and significant changes in prespecified secondary outcomes in the highest treatment dose arm compared to placebo. Fewer patients had a major (>10% or >200 mL) decline in FVC (20 [23.8%] versus 37 [44%], P < 0.01). The adjusted mean absolute change from baseline in total lung capacity (+0.12 L versus −0.24 L, P < 0.001) and resting oxygen saturations (−0.2% versus −1.3%, P = 0.02) were significantly different between the nintedanib 150 mg twice daily group and placebo. SGRQ scores when compared to baseline showed an improved quality of life in the high dose nintedanib group, compared to worsening scores in the placebo group (−0.66 points versus +5.46 points, P = 0.007).Citation57 The magnitude of difference between the two groups exceeds the minimum clinically significant difference in SGRQ of 5 points that has been reported for individuals with IPF.Citation58

Perhaps one of the most striking results in the study was the reduction in acute exacerbations seen in patients receiving 150 mg twice daily compared to placebo (2 [2.3%] versus 12 [13.8%] or 2.4 versus 15.7 per 100 patient years, P = 0.02). The reduction in exacerbation rate appeared to show a dose response effect across the four nintedanib dose groups. Acute exacerbations of IPF are characterized by rapid progression in symptoms and convey a 30-day risk of mortality approaching 50%.Citation59 Prevention of acute exacerbations is therefore an important treatment effect. Some caution must, however, be applied in interpreting this result. Firstly, acute exacerbations are frequently challenging to distinguish from other acute onset respiratory disease, such as infection.Citation60 Secondly, early phase trials of other therapeutic agents in IPF have suggested important effects on rate of acute exacerbations which have not subsequently been borne out in larger Phase III studies.Citation61,Citation62 However, in support of the observed reduction in acute exacerbations in the TOMORROW study, a trend towards lower respiratory-related mortality was observed in both the 100 mg and 150 mg twice daily treatment arms (P = 0.04 and P = 0.06, respectively).

The results of the TOMORROW study were sufficiently positive for Boehringer Ingelheim to undertake two parallel Phase III registration studies of nintedanib in IPF (NCT01335464 and NCT01335477). These studies, IMPULSIS I and II, are identical 52-week trials of nintedanib 150 mg twice daily compared to placebo. As with the TOMORROW study the primary endpoint is annual rate of decline in FVC (expressed in mL over 52 weeks). Target recruitment was approximately 550 subjects for each study. Both trials were initiated in April 2011 and it is anticipated that the final study visit will be conducted in late 2013. It is to be hoped therefore that results will be available in early 2014.

Safety

The safety of nintedanib has been assessed in a number of open label, dose escalation Phase I trials for the treatment of solid cancers where doses up to 500 mg per day have been administered.Citation14,Citation16Citation18,Citation46,Citation47,Citation63,Citation64 Nintedanib has generally been well tolerated in these studies. The most frequently occurring reported adverse events have been nausea, diarrhea, and vomiting. While other anti-angiogenic treatments have been associated with hypertension, this has not been reported with nintedanib.

In line with data from studies in malignancy, the most frequent adverse events reported in the TOMORROW trial were diarrhea (27%), nausea (14.5%), and vomiting (7.7%).Citation11 Serious adverse events rates were similar between groups, although the discontinuation rate due to adverse events was highest in the 150 mg twice daily group at 30.6%. This rate is in comparison to 25.9% in the placebo group and 14.0% in the 100 mg twice daily group. The majority of the reported diarrhea cases were mild or moderate. The rate of gastrointestinal side effects rose with increasing doses of nintedanib, with 8.2% of patients in the maximal dosing arm reporting serious or severe diarrhea compared to 1.2% and 0% in the 50 mg twice daily and placebo arms, respectively. Only 12 subjects (across all arms) discontinued the drug due to diarrhea.

Elevation of liver enzymes occurred more frequently in subjects receiving 300 mg/day of nintedanib when compared to placebo. There were, however, only nine clinically significant episodes of liver enzyme elevation (three times upper limit of normal range) across all of the treatment arms. Only two patients needed to discontinue the drug due to hepatotoxicity, and there were no cases of drug-induced liver failure. All liver function tests normalized with either reduction or discontinuation of nintedanib. Ongoing safety studies include an open label extension of the TOMORROW trial (NCT01170065) and a study, in Japanese subjects, of nintedanib given together with pirfenidone (NCT01417156).

Conclusion

IPF is a progressive and invariably fatal disease. Although the pathogenesis of the condition remains unknown, there is encouraging animal data to suggest that targeting PDGFR, VEGFR, and FGFR ameliorates the development of fibrosis. The multiple targeting of these three profibrotic mediators by the novel tyrosine kinase inhibitor, nintedanib, has led to promising Phase II clinical trial results. Data from the TOMORROW study suggest that high dose oral nintedanib is able to slow the decline of lung function and reduce the rate of acute exacerbations in individuals with mild and moderate IPF. Importantly for patients with this chronic progressive disease, nintedanib also improved quality of life, compared with the placebo. The results of two currently active, parallel, Phase 3, placebo-controlled trials of nintedanib are eagerly awaited. It is to be hoped that these studies will provide verification of the results of the TOMORROW study. Should they do so, nintedanib will become an important and very welcome addition to the therapeutic armamentarium of physicians treating patients with IPF.

Disclosure

Toby M Maher is in receipt of an unrestricted academic industry grant from GlaxoSmithKline. In the last 3 years, TMM has received advisory board or consultancy fees from Actelion, Boehringer Ingelheim, GlaxoSmithKline, InterMune, Respironics, and Sanofi-Aventis. TMM has received speaker’s fees from UCB, Boehringer Ingelheim, and AstraZeneca. TMM’s institution has received an unrestricted educational grant from InterMune. Philip L Molyneaux’s institution has received reimbursement for his conference travel from Boehringer Ingelheim. Hannah V Woodcock has no conflicts of interest to declare.

References

  • Maher TM Wells AU Laurent GJ Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir Journal 2007 30 5 835 839
  • Navaratnam V Fleming KM West J The rising incidence of idiopathic pulmonary fibrosis in the UK Thorax 2011 66 6 462 467 21525528
  • Gribbin J Hubbard RB Le JI Smith CJ West J Tata LJ Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK Thorax 2006 61 11 980 985 16844727
  • Raghu G Weycker D Edelsberg J Bradford WZ Oster G Incidence and prevalence of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2006 174 7 810 816 16809633
  • Navaratnam V Fogarty A Glendening R McKeever T Hubbard RB The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010 Chest Epub 9 24 2012
  • Ley B Collard HR King TEJr Clinical course and prediction of survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 183 4 431 440 20935110
  • Datta A Scotton CJ Chambers RC Novel therapeutic approaches for pulmonary fibrosis Br J Pharmacol 2011 163 1 141 172 21265830
  • King TEJr Pardo A Selman M Idiopathic pulmonary fibrosis Lancet 2011 378 9807 1949 1961 21719092
  • Maher TM Pirfenidone in idiopathic pulmonary fibrosis Drugs Today (Barc) 2010 46 7 473 482 20683502
  • Roth GJ Heckel A Colbatzky F Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J Med Chem 2009 52 14 4466 4480 19522465
  • Richeldi L Costabel U Selman M Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 2011 365 12 1079 1087 21992121
  • Hilberg F Roth GJ Krssak M BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 2008 68 12 4774 4782 18559524
  • Santos ES Gomez JE Raez LE Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor Invest New Drugs 2012 30 3 1261 1269 21350804
  • Ellis PM Kaiser R Zhao Y Stopfer P Gyorffy S Hanna N Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients Clinical Cancer Res 2010 16 10 2881 2889 20460487
  • du Bois A Huober J Stopfer P A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies Ann Oncol 2010 21 2 370 375 19889612
  • Doebele RC Conkling P Traynor AM A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 2012 23 8 2094 2102 22345119
  • Kropff M Kienast J Bisping G An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma Anticancer Res 2009 29 10 4233 4238 19846979
  • Ledermann JA Hackshaw A Kaye S Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J Clin Oncol 2011 29 28 3798 3804 21859991
  • Chaudhary NI Roth GJ Hilberg F Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur Respir J 2007 29 5 976 985 17301095
  • Taeger J Moser C Hellerbrand C Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer Mol Cancer Ther 2011 10 11 2157 2167 21885862
  • Akhurst RJ Hata A Targeting the TGFbeta signalling pathway in disease Nat Rev Drug Discov 2012 11 10 790 811 23000686
  • Antoniades HN Bravo MA Avila RE Platelet-derived growth factor in idiopathic pulmonary fibrosis J Clin Invest 1990 86 4 1055 1064 2170444
  • Bonner JC Regulation of PDGF and its receptors in fibrotic diseases Cytokine and Growth Factor Reviews 2004 15 4 255 273 15207816
  • Battegay EJ Raines EW Colbert T Ross R TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression Journal of immunology 1995 154 11 6040 6047
  • Battegay EJ Raines EW Seifert RA Bowen-Pope DF Ross R TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop Cell 1990 63 3 515 524 2171777
  • Kolb M Margetts PJ Anthony DC Pitossi F Gauldie J Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis J Clin Invest 2001 107 12 1529 1536 11413160
  • Yoshida M Sakuma J Hayashi S A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene Proc Nat Academy of Sciences of the United States of America 1995 92 21 9570 9574
  • Rice AB Moomaw CR Morgan DL Bonner JC Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats Am Journal Pathol 1999 155 1 213 221 10393853
  • Abdollahi A Li M Ping G Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J Exp Med 2005 201 6 925 935 15781583
  • Martinet Y Rom WN Grotendorst GR Martin GR Crystal RG Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis N Engl J Med 1987 317 4 202 209 3600711
  • Homma S Nagaoka I Abe H Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung Am J Respir Crit Care Med 1995 152 6 Pt 1 2084 2089 8520779
  • Daniels CE Wilkes MC Edens M Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 2004 114 9 1308 1316 15520863
  • Daniels CE Lasky JA Limper AH Mieras K Gabor E Schroeder DR Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 2010 181 6 604 610 20007927
  • Gurujeyalakshmi G Hollinger MA Giri SN Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level Am Journal Physiol 1999 276 2 Pt 1 L311 L318 9950894
  • Henke C Fiegel V Peterson M Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury J Clin Invest 1991 88 4 1386 1395 1717512
  • Inoue Y King TEJr Barker E Daniloff E Newman LS Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis Am J Respir Crit Care Med 2002 166 5 765 773 12204879
  • Fan H Duan Y Zhou H Selection of peptide ligands binding to fibroblast growth factor receptor 1 IUBMB Life 2002 54 2 67 72 12440521
  • Calandrella N Risuleo G Scarsella G Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor J Exp Cin Cancer Res 2007 26 3 405 409
  • Yu ZH Wang DD Zhou ZY He SL Chen AA Wang J Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice Biol Pharm Bull 2012 35 5 731 736 22687409
  • Olsson AK Dimberg A Kreuger J Claesson-Welsh L VEGF receptor signalling – in control of vascular function Nat Rev Mol Cell Biol 2006 7 5 359 371 16633338
  • Farkas L Farkas D Ask K VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats J Clin Invest 2009 119 5 1298 1311 19381013
  • Renzoni EA Walsh DA Salmon M Interstitial vascularity in fibrosing alveolitis Am J Respir Crit Care Med 2003 167 3 438 443 12406847
  • Keane MP Arenberg DA Lynch JPIII The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis J Immunol 1997 159 3 1437 1443 9233641
  • Nissen LJ Cao R Hedlund EM Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis J Clin Invest 2007 117 10 2766 2777 17909625
  • Hamada N Kuwano K Yamada M Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice J Immunol 2005 175 2 1224 1231 16002726
  • Mross K Stefanic M Gmehling D Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors Clin Cancer Res 2010 16 1 311 319 20028771
  • Okamoto I Kaneda H Satoh T Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors Mol Cancer Ther 2010 9 10 2825 2833 20688946
  • Stopfer P Rathgen K Bischoff D Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers Xenobiotica 2011 41 4 297 311 21204634
  • Gori B Ricciardi S Fulvi A Intagliata S Del Signore E de Marinis F New antiangiogenics in non-small cell lung cancer treatment: vargatef (BIBF 1120) and beyond Ther Clin Risk Manag 2011 7 429 440 22241943
  • Raghu G Collard HR Anstrom KJ Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials Am J Respir Crit Care Med 2012 185 10 1044 1048 22505745
  • du Bois RM Nathan SD Richeldi L Schwarz MI Noble PW Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials Am J Respir Crit Care Med 2012 186 8 712 715 22798316
  • Wells AU Behr J Costabel U European IPFCG Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 2012 67 11 938 940 23047830
  • du Bois RM Weycker D Albera C Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 184 4 459 466 21616999
  • Taniguchi H Ebina M Kondoh Y Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 2010 35 4 821 829 19996196
  • Collard HR Idiopathic pulmonary fibrosis and pirfenidone Eur Respir J 2010 35 4 728 729 20356985
  • Richeldi L Brown KK Costabel U Efficacy of the tyrosine kinase inhibitor BIBF 1120 in patients with IPF: consistent pattern of primary endpoint results in sensitivity analyses of the TOMORROW trial Am J Respir Crit Care Med 2012 185 1 Meeting Abstracts A3633
  • Brown KK Richeldi L Costabel U Treatment of IPF with the tyrosine kinase inhibitor BIBF 1120: patient-reported outcomes in the TOMORROW trial Am Journal of Respiratory and Critical Care Medicine 2012 185 1 Meeting Abstracts A3634
  • Swigris JJ Brown KK Behr J The SF-36 and SGRQ: validity and first look at minimum important differences in IPF Respir Med 2010 104 2 296 304 19815403
  • Collard HR Moore BB Flaherty KR Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2007 176 7 636 643 17585107
  • Huie TJ Olson AL Cosgrove GP A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes Respirology 2010 15 6 909 917 20546190
  • Azuma A Nukiwa T Tsuboi E Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2005 171 9 1040 1047 15665326
  • Noble PW Albera C Bradford WZ Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 2011 377 9779 1760 1769 21571362
  • Bouche O Maindrault-Goebel F Ducreux M Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer Anticancer Res 2011 31 6 2271 2281 21737652
  • Reck M Kaiser R Eschbach C A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann Oncol 2011 22 6 1374 1381 21212157